An ocular view of the IGF-IGFBP system

Growth Hormone and IGF Research

Volumn 23, Issue 3, 2013, Pages 45-52

  Nguyen, Dung V ^a   Li Calzi, Sergio ^a   Shaw, Lynn C ^a   Kielczewski, Jennifer L ^a   Korah, Hannah E ^a   Grant, Maria B ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Blood retinal barrier; Hypoxia; IGF; IGF binding protein; Retinopathy; Vascular protection

Indexed keywords

SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BINDING AFFINITY; BLOOD RETINA BARRIER; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DIABETIC RETINOPATHY; DOWN REGULATION; FIBROSIS; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; HYPERTENSION RETINOPATHY; HYPOXIA; IMMUNOREACTIVITY; MICROENVIRONMENT; MICROGLIA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RETROLENTAL FIBROPLASIA; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; VITREORETINOPATHY;

ANIMALS; EYE DISEASES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I;

EID: 84876716247     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2013.03.001     Document Type: Review

References (119)

1. Ferry R.J., Cerri R.W., Cohen P. Insulin-like growth factor binding proteins: new proteins, new functions. Horm. Res. 1999, 51:53-67.
2. Baxter R.C., Martin J.L. Binding proteins for the insulin-like growth factors: structure, regulation and function. Prog. Growth Factor Res. 1989, 1:49-68.
3. Chang K.-H., Chan-Ling T., McFarland E.L., Afzal A., Pan H., Baxter L.C., et al. IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:10595-10600.
4. Shimasaki S., Ling N. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). Prog. Growth Factor Res. 1991, 3:243-266.
5. Rechler M.M. Insulin-like growth factor binding proteins. Vitam. Horm. 1993, 47:1-114.
6. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995, 16:3-34.
7. Rosenfeld R.G., Lamson G., Pham H., Oh Y., Conover C., De Leon D.D., et al. Insulinlike growth factor-binding proteins. Recent Prog. Horm. Res. 1990, 46:99-159. (discussion 159-63).
8. Zapf J. Physiological role of the insulin-like growth factor binding proteins. Eur. J. Endocrinol. 1995, 132:645-654.
9. Lamson G., Giudice L.C., Rosenfeld R.G. Insulin-like growth factor binding proteins: structural and molecular relationships. Growth Factors 1991, 5:19-28.
10. Rodgers B.D., Roalson E.H., Thompson C. Phylogenetic analysis of the insulin-like growth factor binding protein (IGFBP) and IGFBP-related protein gene families. Gen. Comp. Endocrinol. 2008, 155:201-207.
11. Ruan W., Lai M. Insulin-like growth factor binding protein: a possible marker for the metabolic syndrome?. Acta Diabetol. 2010, 47:5-14.
12. Firth S.M., Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 2002, 23:824-854.
13. Higashi Y., Sukhanov S., Anwar A., Shai S.-Y., Delafontaine P. Aging, atherosclerosis, and IGF-1. J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67:626-639.
14. Grant M.B., Schmetz I., Russell B., Harwood H.J., Silverstein J., Merimee T.J. Changes in insulin-like growth factors I and II and their binding protein after a single intramuscular injection of growth hormone. J. Clin. Endocrinol. Metab. 1986, 63:981-984.
15. Schultz G.S., Grant M.B. Neovascular growth factors. Eye (Lond.) 1991, 5(Pt 2):170-180.
16. Gluckman P.D. Clinical review 68: the endocrine regulation of fetal growth in late gestation: the role of insulin-like growth factors. J. Clin. Endocrinol. Metab. 1995, 80:1047-1050.
17. Löfqvist C., Niklasson A., Engström E., Friberg L.E., Camacho-Hübner C., Ley D., et al. A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants. Pediatr. Res. 2009, 65:574-579.
18. Hellström A., Engström E., Hård A.-L., Albertsson-Wikland K., Carlsson B., Niklasson A., et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003, 112:1016-1020.
19. Cobb L.J., Salih D.A.M., Gonzalez I., Tripathi G., Carter E.J., Lovett F., et al. Partitioning of IGFBP-5 actions in myogenesis: IGF-independent anti-apoptotic function. J. Cell Sci. 2004, 117:1737-1746.
20. Salih D.A.M., Tripathi G., Holding C., Szestak T.A.M., Gonzalez M.I., Carter E.J., et al. Insulin-like growth factor-binding protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in mice. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:4314-4319.
21. Samuel W., Kutty R.K., Vijayasarathy C., Pascual I., Duncan T., Redmond T.M. Decreased expression of insulin-like growth factor binding protein-5 during N-(4-hydroxyphenyl)retinamide-induced neuronal differentiation of ARPE-19 human retinal pigment epithelial cells: regulation by CCAAT/enhancer-binding protein. J. Cell. Physiol. 2010, 224:827-836.
22. Delafontaine P., Song Y.-H., Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler. Thromb. Vasc. Biol. 2004, 24:435-444.
23. Shai S.-Y., Sukhanov S., Higashi Y., Vaughn C., Kelly J., Delafontaine P. Smooth muscle cell-specific insulin-like growth factor-1 overexpression in Apoe-/- mice does not alter atherosclerotic plaque burden but increases features of plaque stability. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1916-1924.
24. Libby P., Sasiela W. Plaque stabilization: can we turn theory into evidence?. Am. J. Cardiol. 2006, 98:26P-33P.
25. Shai S.-Y., Sukhanov S., Higashi Y., Vaughn C., Rosen C.J., Delafontaine P. Low circulating insulin-like growth factor I increases atherosclerosis in ApoE-deficient mice. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:H1898-H1906.
26. Rajwani A., Ezzat V., Smith J., Yuldasheva N.Y., Duncan E.R., Gage M., et al. Increasing circulating IGFBP1 levels improves insulin sensitivity, promotes nitric oxide production, lowers blood pressure, and protects against atherosclerosis. Diabetes 2012, 61:915-924.
27. Wang J., Razuvaev A., Folkersen L., Hedin E., Roy J., Brismar K., et al. The expression of IGFs and IGF binding proteins in human carotid atherosclerosis, and the possible role of IGF binding protein-1 in the regulation of smooth muscle cell proliferation. Atherosclerosis 2012, 220:102-109.
28. Rajah R., Valentinis B., Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J. Biol. Chem. 1997, 272:12181-12188.
29. Harms K.L., Chen X. The C terminus of p53 family proteins is a cell fate determinant. Mol. Cell. Biol. 2005, 25:2014-2030.
30. Lee K.-W., Ma L., Yan X., Liu B., Zhang X., Cohen P. Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRalpha/Nur77. J. Biol. Chem. 2005, 280:16942-16948.
31. Mehta H.H., Gao Q., Galet C., Paharkova V., Wan J., Said J., et al. IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res. 2011, 71:5154-5163.
32. Liu B., Lee K.-W., Anzo M., Zhang B., Zi X., Tao Y., et al. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene 2007, 26:1811-1819.
33. Grkovic S., O'Reilly V.C., Han S., Hong M., Baxter R.C., Firth S.M. IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments. Oncogene 2012, 1-9.
34. Ingermann A.R., Yang Y.-F., Han J., Mikami A., Garza A.E., Mohanraj L., et al. Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer. J. Biol. Chem. 2010, 285:30233-30246.
35. D'Ercole A.J., Stiles A.D., Underwood L.E. Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:935-939.
36. King G.L., Goodman A.D., Buzney S., Moses A., Kahn C.R. Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J. Clin. Invest. 1985, 75:1028-1036.
37. Grant M., Jerdan J., Merimee T.J. Insulin-like growth factor-I modulates endothelial cell chemotaxis. J. Clin. Endocrinol. Metab. 1987, 65:370-371.
38. Grant M., Russell B., Fitzgerald C., Merimee T.J. Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization. Diabetes 1986, 35:416-420.
39. Walker J.L., Zhang L., Zhou J., Woolkalis M.J., Menko A.S. Role for alpha 6 integrin during lens development: evidence for signaling through IGF-1R and ERK. Dev. Dyn. 2002, 223:273-284.
40. Rosenthal R., Wohlleben H., Malek G., Schlichting L., Thieme H., Bowes Rickman C., et al. Insulin-like growth factor-1 contributes to neovascularization in age-related macular degeneration. Biochem. Biophys. Res. Commun. 2004, 323:1203-1208.
41. Zygar C.A., Colbert S., Yang D., Fernald R.D. IGF-1 produced by cone photoreceptors regulates rod progenitor proliferation in the teleost retina. Brain Res. Dev. Brain Res. 2005, 154:91-100.
42. Li F., Cao W., Steinberg R.H., LaVail M.M. Basic FGF-induced down-regulation of IGF-I mRNA in cultured rat Müller cells. Exp. Eye Res. 1999, 68:19-27.
43. Shaw L.C., Pan H., Afzal a, Calzi S.L., Spoerri P.E., Sullivan S.M., et al. Proliferating endothelial cell-specific expression of IGF-I receptor ribozyme inhibits retinal neovascularization. Gene Ther. 2006, 13:752-760.
44. Ishikawa K., Yoshida S., Kadota K., Nakamura T., Niiro H., Arakawa S., et al. Gene expression profile of hyperoxic and hypoxic retinas in a mouse model of oxygen-induced retinopathy. Investig. Ophthalmol. Vis. Sci. 2010, 51:4307-4319.
45. Lofqvist C., Willett K.L., Aspegren O., Smith A.C.H., Aderman C.M., Connor K.M., et al. Quantification and localization of the IGF/insulin system expression in retinal blood vessels and neurons during oxygen-induced retinopathy in mice. Investig. Ophthalmol. Vis. Sci. 2009, 50:1831-1837.
46. Kondo T., Vicent D., Suzuma K., Yanagisawa M., King G.L., Holzenberger M., et al. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J. Clin. Invest. 2003, 111:1835-1842.
47. Guidry C., King J.L. Isolation and characterization of vitreous insulin-like growth factor binding proteins. Investig. Ophthalmol. Vis. Sci. 2011, 52:303-309.
48. Schoen T.J., Waldbillig R.J., Searcy G., Gaudet S.J., Jones B.E., Chader G.J., et al. Identification and partial characterization of a proteinase specific for insulin-like growth factor binding protein-3 in aqueous and vitreous humors. Curr. Eye Res. 1995, 14:127-135.
49. Bergman P.B., Moravski C.J., Edmondson S.R., Russo V.C., Bach L.a, Wilkinson-Berka J.L., et al. Expression of the IGF system in normal and diabetic transgenic (mRen-2)27 rat eye. Investig. Ophthalmol. Vis. Sci. 2005, 46:2708-2715.
50. Mullins J.J., Peters J., Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990, 344:541-544.
51. Meyer-Schwickerath R., Pfeiffer A., Blum W.F., Freyberger H., Klein M., Lösche C., et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J. Clin. Invest. 1993, 92:2620-2625.
52. Spranger J., Bühnen J., Jansen V., Krieg M., Meyer-Schwickerath R., Blum W.F., et al. Systemic levels contribute significantly to increased intraocular IGF-I, IGF-II and IGF-BP3 [correction of IFG-BP3] in proliferative diabetic retinopathy. Horm. Metab. Res. 2000, 32:196-200.
53. Spranger J., Möhlig M., Osterhoff M., Bühnen J., Blum W.F., Pfeiffer A.F. Retinal photocoagulation does not influence intraocular levels of IGF-I, IGF-II and IGF-BP3 in proliferative diabetic retinopathy-evidence for combined treatment of PDR with somatostatin analogues and retinal photocoagulation?. Horm. Metab. Res. 2001, 33:312-316.
54. Kielczewski J.L., Jarajapu Y.P.R., McFarland E.L., Cai J., Afzal A., Li Calzi S., et al. Insulin-like growth factor binding protein-3 mediates vascular repair by enhancing nitric oxide generation. Circ. Res. 2009, 105:897-905.
55. Segal M.S., Shah R., Afzal A., Perrault C.M., Chang K., Schuler A., et al. Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. Diabetes 2006, 55:102-109.
56. Li Calzi S., Purich D.L., Chang K.H., Afzal A., Nakagawa T., Busik J.V., et al. Carbon monoxide and nitric oxide mediate cytoskeletal reorganization in microvascular cells via vasodilator-stimulated phosphoprotein phosphorylation: evidence for blunted responsiveness in diabetes. Diabetes 2008, 57:2488-2494.
57. Lofqvist C., Chen J., Connor K.M., Smith A.C.H., Aderman C.M., Liu N., et al. IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:10589-10594.
58. Kielczewski J.L., Hu P., Shaw L.C., Li Calzi S., Mames R.N., Gardiner T.a, et al. Novel protective properties of IGFBP-3 result in enhanced pericyte ensheathment, reduced microglial activation, increased microglial apoptosis, and neuronal protection after ischemic retinal injury. Am. J. Pathol. 2011, 178:1517-1528.
59. Davies M.H., Eubanks J.P., Powers M.R. Microglia and macrophages are increased in response to ischemia-induced retinopathy in the mouse retina. Mol. Vis. 2006, 12:467-477.
60. Lee Y.-C., Jogie-Brahim S., Lee D.-Y., Han J., Harada A., Murphy L.J., et al. Insulin-like growth factor-binding protein-3 (IGFBP-3) blocks the effects of asthma by negatively regulating NF-κB signaling through IGFBP-3R-mediated activation of caspases. J. Biol. Chem. 2011, 286:17898-17909.
61. Jeschke M.G., Barrow R.E., Herndon D.N. Insulinlike growth factor I plus insulinlike growth factor binding protein 3 attenuates the proinflammatory acute phase response in severely burned children. Ann. Surg. 2000, 231:246-252.
62. Spies M., Wolf S.E., Barrow R.E., Jeschke M.G., Herndon D.N. Modulation of types I and II acute phase reactants with insulin-like growth factor-1/binding protein-3 complex in severely burned children. Crit. Care Med. 2002, 30:83-88.
63. Jarajapu Y.P.R., Cai J., Yan Y., Li Calzi S., Kielczewski J.L., Hu P., et al. Protection of blood retinal barrier and systemic vasculature by insulin-like growth factor binding protein-3. PLoS One 2012, 7:e39398.
64. Zhang X., Bao S., Lai D., Rapkins R.W., Gillies M.C. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 2008, 57:1026-1033.
65. Kielczewski J.L., Li Calzi S., Shaw L.C., Cai J., Qi X., Ruan Q., et al. Free insulin-like growth factor binding protein-3 (IGFBP-3) reduces retinal vascular permeability in association with a reduction of acid sphingomyelinase (ASMase). Investig. Ophthalmol. Vis. Sci. 2011, 52:8278-8286.
66. Miller E.C., Capps B.E., Sanghani R.R., Clemmons D.R., Maile L.a Regulation of igf-I signaling in retinal endothelial cells by hyperglycemia. Investig. Ophthalmol. Vis. Sci. 2007, 48:3878-3887.
67. Yuhanna I.S., Zhu Y., Cox B.E., Hahner L.D., Osborne-Lawrence S., Lu P., et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 2001, 7:853-857.
68. Trigatti B., Rigotti A., Krieger M. The role of the high-density lipoprotein receptor SR-BI in cholesterol metabolism. Curr. Opin. Lipidol. 2000, 11:123-131.
69. Nofer J.-R., van der Giet M., Tölle M., Wolinska I., von Wnuck Lipinski K., Baba H.A., et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 2004, 113:569-581.
70. Wilson S.H., Davis M.I., Caballero S., Grant M.B. Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues: implications for diabetic retinopathy. Growth Horm. IGF Res. 2001, 11(Suppl. A):S53-S59.
71. Ning A., Cui J., Maberley D., Ma P., Matsubara J. Expression of integrins in human proliferative diabetic retinopathy membranes. Can. J. Ophthalmol. 2008, 43:683-688.
72. Spoerri P.E., Caballero S., Wilson S.H., Shaw L.C., Grant M.B. Expression of IGFBP-3 by human retinal endothelial cell cultures: IGFBP-3 involvement in growth inhibition and apoptosis. Investig. Ophthalmol. Vis. Sci. 2003, 44:365-369.
73. Yoo E.-G., Lee W.J., Kim J.H., Chae H.-W., Hyun S.E., Kim D.H., et al. Insulin-like growth factor-binding protein-3 mediates high glucose-induced apoptosis by increasing oxidative stress in proximal tubular epithelial cells. Endocrinology 2011, 152:3135-3142.
74. Crawford T.N., Alfaro D.V., Kerrison J.B., Jablon E.P. Diabetic retinopathy and angiogenesis. Curr. Diabetes Rev. 2009, 5:8-13.
75. Rho S.B., Dong S.M., Kang S., Seo S.-S., Yoo C.W., Lee D.O., et al. Insulin-like growth factor-binding protein-5 (IGFBP-5) acts as a tumor suppressor by inhibiting angiogenesis. Carcinogenesis 2008, 29:2106-2111.
76. Contois L.W., Nugent D.P., Caron J.M., Cretu A., Tweedie E., Akalu A., et al. Insulin-like growth factor binding protein-4 differentially inhibits growth factor-induced angiogenesis. J. Biol. Chem. 2012, 287:1779-1789.
77. Prêle C.M., Reichelt M.E., Mutsaers S.E., Davies M., Delbridge L.M., Headrick J.P., et al. Insulin-like growth factor-1 overexpression in cardiomyocytes diminishes ex vivo heart functional recovery after acute ischemia. Cardiovasc. Pathol. 2012, 21:17-27.
78. Panjala S.R., Thomas S.a, Steinle J.J. Effects of insulin-like growth factor-1 (IGF-1) receptor signaling on rates of apoptosis in retina of dopamine beta hydroxylase (Dbh-/-) knockout mice. Auton. Neurosci. 2010, 152:21-26.
79. Wu Y.-C., Buckner B.R., Zhu M., Cavanagh H.D., Robertson D.M. Elevated IGFBP3 levels in diabetic tears: a negative regulator of IGF-1 signaling in the corneal epithelium. Ocul. Surf. 2012, 10:100-107.
80. Merimee T.J., Zapf J., Froesch E.R. Insulin-like growth factors. Studies in diabetics with and without retinopathy. N. Engl. J. Med. 1983, 309:527-530.
81. Dills D.G., Moss S.E., Klein R., Klein B.E. Association of elevated IGF-I levels with increased retinopathy in late-onset diabetes. Diabetes 1991, 40:1725-1730.
82. Hyer S.L., Sharp P.S., Brooks R.A., Burrin J.M., Kohner E.M. A two-year follow-up study of serum insulinlike growth factor-I in diabetics with retinopathy. Metab. Clin. Exp. 1989, 38:586-589.
83. Chantelau E., Eggert H., Seppel T., Schönau E., Althaus C. Elevation of serum IGF-1 precedes proliferative diabetic retinopathy in Mauriac's syndrome. Br. J. Ophthalmol. 1997, 81:169-170.
84. Feldmann B., Jehle P.M., Mohan S., Lang G.E., Lang G.K., Brueckel J., et al. Diabetic retinopathy is associated with decreased serum levels of free IGF-I and changes of IGF-binding proteins. Growth Horm. IGF Res. 2000, 10:53-59.
85. Frystyk J., Bek T., Flyvbjerg A., Skjaerbaek C., Ørskov H. The relationship between the circulating IGF system and the presence of retinopathy in type 1 diabetic patients. Diabet. Med. 2003, 20:269-276.
86. Fujihara M., Uemasu J., Kawasaki H. Serum and urinary levels of insulin-like growth factor I in patients with chronic renal disease and diabetes mellitus: its clinical implication. Clin. Nephrol. 1996, 45:372-378.
87. Wedrychowicz A., Dziatkowiak H., Nazim J., Sztefko K. Insulin-like growth factor-1 and its binding proteins, IGFBP-1 and IGFBP-3, in adolescents with type-1 diabetes mellitus and microalbuminuria. Horm. Res. 2005, 63:245-251.
88. Bereket A., Lang C.H., Wilson T.A. Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus. Horm. Metab. Res. 1999, 31:172-181.
89. Chiarelli F., Giannini C., Mohn A. Growth, growth factors and diabetes. Eur. J. Endocrinol. 2004, 151:U109-U117. (Suppl.).
90. Feldmann B., Lang G.E., Arnavaz A., Jehle P.M., Böhm B.O., Lang G.K. Decreased serum level of free bioavailable IGF-I in patients with diabetic retinopathy. Ophthalmologe 1999, 96:300-305.
91. Capoluongo E., Pitocco D., Lulli P., Minucci A., Santonocito C., Manto A., et al. Inverse correlation between serum free IGF-I and IGFBP-3 levels and blood pressure in patients affected with type 1 diabetes. Cytokine 2006, 34:303-311.
92. Payne J.F., Tangpricha V., Cleveland J., Lynn M.J., Ray R., Srivastava S.K. Serum insulin-like growth factor-I in diabetic retinopathy. Mol. Vis. 2011, 17:2318-2324.
93. Pastor J.C., Universitario I., Aplicada D.O. Major review proliferative vitreoretinopathy: an overview 1998, 43.
94. Charteris D.G., Sethi C.S., Lewis G.P., Fisher S.K. Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology. Eye (Lond.) 2002, 16:369-374.
95. Pastor J.C., de la Rúa E.R., Martín F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog. Retin. Eye Res. 2002, 21:127-144.
96. Grierson I., Mazure A., Hogg P., Hiscott P., Sheridan C., Wong D. Non-vascular vitreoretinopathy: the cells and the cellular basis of contraction. Eye (Lond.) 1996, 10(Pt 6):671-684.
97. Peters M.A., Burke J.M., Clowry M., Abrams G.W., Williams G.A. Development of traction retinal detachments following intravitreal injections of retinal Muller and pigment epithelial cells. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. 1986, 224:554-563.
98. Yang C.H., Huang T.F., Liu K.R., Chen M.S., Hung P.T. Inhibition of retinal pigment epithelial cell-induced tractional retinal detachment by disintegrins, a group of Arg-Gly-Asp-containing peptides from viper venom. Investig. Ophthalmol. Vis. Sci. 1996, 37:843-854.
99. Wong C.A., Potter M.J., Cui J.Z., Chang T.S., Ma P., Maberley A.L., et al. Induction of proliferative vitreoretinopathy by a unique line of human retinal pigment epithelial cells. Can. J. Ophthalmol. 2002, 37:211-220.
100. Khaliq A., Jarvis-Evans J., McLeod D., Boulton M. Oxygen modulates the response of the retinal pigment epithelium to basic fibroblast growth factor and epidermal growth factor by receptor regulation. Investig. Ophthalmol. Vis. Sci. 1996, 37:436-443.
101. Hiscott P., Sheridan C., Magee R.M., Grierson I. Matrix and the retinal pigment epithelium in proliferative retinal disease. Prog. Retin. Eye Res. 1999, 18:167-190.
102. Mukherjee S., King J.L., Guidry C. Phenotype-associated changes in retinal pigment epithelial cell expression of insulin-like growth factor binding proteins. Investig. Ophthalmol. Vis. Sci. 2009, 50:5449-5455.
103. Mukherjee S., Guidry C. The insulin-like growth factor system modulates retinal pigment epithelial cell tractional force generation. Investig. Ophthalmol. Vis. Sci. 2007, 48:1892-1899.
104. Sureshbabu A., Okajima H., Yamanaka D., Shastri S., Tonner E., Rae C., et al. IGFBP-5 induces epithelial and fibroblast responses consistent with the fibrotic response. Biochem. Soc. Trans. 2009, 37:882-885.
105. Yasuoka H., Yamaguchi Y., Feghali-Bostwick C.a The pro-fibrotic factor IGFBP-5 induces lung fibroblast and mononuclear cell migration. Am. J. Respir. Cell Mol. Biol. 2009, 41:179-188.
106. Moysidis S.N., Thanos A., Vavvas D.G. Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside. Mediat. Inflamm. 2012, 2012:815937.
107. Klein R., Klein B.E., Moss S.E., Wang Q. Hypertension and retinopathy, arteriolar narrowing, and arteriovenous nicking in a population. Arch. Ophthalmol. 1994, 112:92-98.
108. Katsi V., Marketou M., Vlachopoulos C., Tousoulis D., Souretis G., Papageorgiou N., et al. Impact of arterial hypertension on the eye. Curr. Hypertens. Rep. 2012, 14:581-590.
109. Wong T.Y., Klein R., Klein B.E.K., Meuer S.M., Hubbard L.D. Retinal vessel diameters and their associations with age and blood pressure. Investig. Ophthalmol. Vis. Sci. 2003, 44:4644-4650.
110. Sowers J.R. Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 1997, 29:691-699.
111. Zhang L., Curhan G.C., Forman J.P. Plasma insulin-like growth factor-1 level and risk of incident hypertension in nondiabetic women. J. Hypertens. 2011, 29:229-235.
112. Sharrett A.R., Hubbard L.D., Cooper L.S., Sorlie P.D., Brothers R.J., Nieto F.J., et al. Retinal arteriolar diameters and elevated blood pressure: the atherosclerosis risk in communities study. Am. J. Epidemiol. 1999, 150:263-270.
113. Wong T.Y., Hubbard L.D., Klein R., Marino E.K., Kronmal R., Sharrett A.R., et al. Retinal microvascular abnormalities and blood pressure in older people: the cardiovascular health study. Br. J. Ophthalmol. 2002, 86:1007-1013.
114. Landi F., Russo A., Cesari M., Barillaro C., Onder G., Zamboni V., et al. The ilSIRENTE study: a prospective cohort study on persons aged 80years and older living in a mountain community of Central Italy. Aging Clin. Exp. Res. 2005, 17:486-493.
115. Onder G., Liperoti R., Russo A., Capoluongo E., Minucci A., Lulli P., et al. Use of ACE inhibitors is associated with elevated levels of IGFBP-3 among hypertensive older adults: results from the IlSIRENTE study. Eur. J. Clin. Pharmacol. 2007, 63:389-395.
116. Rabb M.F., Gagliano D.A., Teske M.P. Retinal arterial macroaneurysms. Surv. Ophthalmol. 1988, 33:73-96.
117. DellaCroce J.T., Vitale A.T. Hypertension and the eye. Curr. Opin. Ophthalmol. 2008, 19:493-498.
118. Abu-Safieh L., Abboud E.B., Alkuraya H., Shamseldin H., Al-Enzi S., Al-Abdi L., et al. Mutation of IGFBP7 causes upregulation of BRAF/MEK/ERK pathway and familial retinal arterial macroaneurysms. Am. J. Hum. Genet. 2011, 89:313-319.
119. López-Bermejo A., Khosravi J., Ricart W., Castro A., Hwa V., Pratt K.L., et al. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1/MAC25) is linked to endothelial-dependent vasodilation in high-ferritin type 2 diabetes. Diabetes Care 2007, 30:1615-1617.